Neurodex Faces Review Prolongation Due To QT Submission

Priority review of the involuntary emotional expression disorder therapy is extended by 90 days to allow for sufficient consideration of newly submitted data.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet